Is it safe to take GLP-1 medications with kidney disease?

GLP-1 medications can be used in patients with chronic kidney disease and may actually provide kidney protective benefits. The FLOW trial demonstrated that semaglutide reduced kidney disease progression and cardiovascular death by 24% in patients with type 2 diabetes and CKD. However, severe nausea, vomiting, and diarrhea from GLP-1s can cause dehydration that worsens kidney function. For patients with severe CKD (Stage 4-5, eGFR <30), starting doses should be lower and titration slower. No dose adjustment is needed for mild-moderate CKD (Stages 1-3). Acute kidney injury has been reported with severe GI side effects, so hydration is critical. Some providers check baseline kidney function and monitor periodically, especially when doses are increased. The kidney benefits appear independent of glucose lowering and weight loss, suggesting direct protective mechanisms.